高免赔额健康计划对乳房再造的影响:财务毒性考量
基于MarketScan 2014至2017年数据,比较高免赔额健康计划(HDHP)与低免赔额健康计划(LDHP)下乳房切除术、乳房再造(即刻与延期)、乳房修整和缩乳术的使用率、季节性与自付费用。HDHP与LDHP的乳房切除术和乳房再造年使用率差异很小;除即刻乳房再造外,乳房切除术、延期乳房再造和择期乳房手术第四季度使用显著增加(P < 0.001);无论时机与再造方式,HDHP自付费用中位数均显著高于LDHP(均P < 0.001)。
要点
- HDHP与LDHP的乳房切除术和乳房再造年使用率差异很小。
- 除即刻乳房再造外,乳房切除术、延期乳房再造和择期乳房手术第四季度使用显著增加(P < 0.001)。
- 无论手术时机与再造方式,HDHP自付费用中位数均显著高于LDHP(均P < 0.001)。
核心结论
- LDHP与HDHP的乳房切除术和乳房再造率无差异,但除即刻乳房再造外所有乳房手术均存在季节性,提示女性是理性经济行为者。
- 无论服务时机和再造方式,HDHP患者自付费用均高于LDHP患者,这为提供者参与财务毒性讨论提供了良好起点。
研究设计与样本
- 查询MarketScan 2014至2017年乳房切除术、乳房再造(即刻和延期)、乳房修整和缩乳术病例。
- 仅纳入指数手术后完整日历年持续参保的患者。
- 根据自付费用分担比较HDHP与低免赔额健康计划(LDHP)。
主要发现
- LDHP与HDHP的乳房切除术和乳房再造年使用率差异很小。
- 乳房切除术、延期乳房再造和择期乳房手术第四季度使用显著增加(P < 0.001),而即刻乳房再造未显示此变化。
- 无论时机和再造方法,HDHP自付费用中位数均显著高于LDHP(均P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-deductible health plans (HDHPs) are used within the United States to curb unnecessary health care spending; however, the resulting increased out-of-pocket (OOP) costs may be associated with financial toxicity. The aim was to assess the impact of HDHPs on use and seasonality of mastectomy and breast reconstruction procedures. The hypothesis is that the high OOP costs of HDHPs will lead to decreased overall service use and greater fourth-quarter use after the deductible has been met. METHODS: MarketScan was queried from 2014 to 2017 for episodes of mastectomy, breast reconstruction (immediate and delayed), breast revision, and reduction. Only patients continuously enrolled for the full calendar year after the index operation were included. HDHPs and low-deductible health plans (LDHPs) were compared based on OOP cost sharing. Outcomes included surgery use rates, seasonality of operations, and median/mean OOP costs. RESULTS: Annual mastectomy and breast reconstruction use rates varied little between LDHPs and HDHPs. Mastectomies, delayed breast reconstruction, and elective breast procedures (P < 0.001) all showed significant increases in fourth-quarter use, whereas immediate breast reconstruction did not. Regardless of timing and reconstruction method, HDHPs had significantly greater median OOP costs compared to LDHPs (all P < 0.001). CONCLUSIONS: Mastectomy and breast reconstruction rates did not differ between LDHPs and HDHPs, but seasonality for all breast procedures was measured with the exception of immediate breast reconstruction, suggesting that women are rational economic actors. Regardless of service timing and reconstruction modality, HDHP patients had greater OOP costs compared to LDHP patients, which serves as a good starting point for provider engagement in financial toxicity.
引用
- Shamsunder MG, Sheckter CC, Sheinin A, et al. Impact of High-Deductible Health Plans on Breast Reconstruction: Considerations for Financial Toxicity. Plast Reconstr Surg. 2022. PMID: 36696302. doi:10.1097/PRS.0000000000009823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。